A share price of Akero Therapeutics Inc [AKRO] is currently trading at $31.20, up 1.84%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AKRO shares have gain 4.84% over the last week, with a monthly amount glided 8.82%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on November 18, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $65. On September 19, 2023, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $69 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $83 on August 28, 2023. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $65 on January 27, 2023. Evercore ISI upgraded its rating to Outperform for this stock on September 14, 2022, and upped its price target to $50. In a note dated October 19, 2021, Morgan Stanley downgraded an Equal-Weight rating on this stock but restated the target price of $27.
Akero Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $15.32 and $37.00. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $31.20 at the most recent close of the market. An investor can expect a potential return of 47.44% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -948.14%, Pretax Profit Margin comes in at -835.29%, and Net Profit Margin reading is -835.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.33 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.36 points at the first support level, and at 29.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.66, and for the 2nd resistance point, it is at 32.11.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Akero Therapeutics Inc [NASDAQ:AKRO] is 17.25. In addition, the Quick Ratio stands at 17.25 and the Cash Ratio stands at 7.3.
Transactions by insiders
Recent insider trading involved Yale Catriona, Chief Development Officer, that happened on Nov 15 ’24 when 9061.0 shares were sold. Chief Development Officer, Yale Catriona completed a deal on Nov 06 ’24 to sell 10000.0 shares. Meanwhile, Officer CATRIONA YALE bought 10000.0 shares on Nov 06 ’24.
